ACSEP develops LXO partnership to drive digitalisation strategies

ACSEP has been a long-standing partner in advancing the digital transformation of LXO Group (“LXO”), a leading platform for established medicines across multiple therapeutic areas.

LXO, a fast growing group

Founded in 2015, LXO acquires mature drugs from major pharmaceutical companies in areas such as central nervous system disorders, cardiology, pain management, oral health as well as women’s health, with the aim of revitalising and relaunching them both in France and internationally. Over the past decade, LXO has grown its revenue from zero to €90 million. A significant driver for this growth has been through the support received from ACSEP for its digitalisation processes thus enabling LXO to gain a true competitive advantage in the market.

“We needed to consolidate and automate our existing data management, enabling our teams to be more agile and focus on high-value activities”, explains Karine PINON, co-founder and CEO of LXO Group. “Additionally, we work with numerous subcontractors and partners for drug production, logistics and distribution, so having precise KPIs for all these activities was essential.”

Digitalisation at the heart of LXO’s strategy

ACSEP initial project involved to implementing Sage for financial and supply chain activities complemented by the development of reporting tools and performance indicators. Arnaud PAUSÉ, Director of ASCEP’s Consultancy branch, explained: “LXO aimed to minimise manual data entry, which is both time-consuming and often error prone. They also needed real-time access to key data across all departments. Our solution now ensures automatic data integration, providing LXO with shared dashboards and indicators to improve decision making.”

Currently, all LXO employees benefit from access to common indicators to streamline decisions, and ACSEP is further assisting in publishing sales’ KPIs for LXO medicines which are distributed in over 60 countries.

“Since being backed by Stanley Capital in 2022, consolidated KPIs have become even more critical for us, adds Pinon. “After our successful collaboration with ACSEP, we plan to scale this approach across all our activities and future acquisitions. ASCEP shares our core values, including service quality, ethics, agility and putting people at the heart of the company – which makes them an ideal partner.”

And tomorrow, a global 3PL tender with ACSEP

Looking ahead, ACSEP is supporting LXO with a 3PL tender for Europe and other global markets, in line the launch of Nimotop, a drug aimed at preventing complications from cerebral aneurysm (subarachnoid vasospasm) and is LXO’s most recent acquisition.

LXO Group is a dynamic French pharmaceutical company focused on non-generic prescription medicines, that are mostly for chronic or recurring diseases and indications, and with proven efficacy and safety and strong brand awareness. LXO holds marketing authorizations in various therapeutic areas such as Cardiovascular, Central Nervous System, and internal medicines. Since its foundation in 2015, LXO has grown substantially through a mix of organic growth and numerous acquisitions that have broadened its product portfolio and its range of expertise. Today, the business brings together teams with expertise in quality management, regulatory, logistics/distribution, marketing and sales. LXO operates as an agile platform, outsourcing all production to leading subcontractors in Europe and the US. The company is committed to being as close as possible to the needs of healthcare professionals and patients for its medicines and medical devices. The business has a turnover of over €90m and a distribution network of more than 80 countries globally. For more information: www.lxogroup.com, LinkedIn & Instagram